Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications*
- 1 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 36 (8) , 2335-2340
- https://doi.org/10.1097/ccm.0b013e31818103ea
Abstract
Background: Methicillin-resistant Staphylococcus aureus causes significant morbidity and mortality. Initially inappropriate antibiotic therapy for methicillin-resistant S. aureus increases the risk for mortality. The impact of initially inappropriate antibiotic therapy on hospital length of stay and costs remains unknown. Methods: We identified patients admitted with nonnosocomial methicillin-resistant S. aureus sterile-site infections during a 3 yr period and compared those given appropriate antibiotic therapy with those given initially inappropriate antibiotic therapy. Appropriate therapy was defined based on timely administration of an anti-infective to which the pathogen was in vitro susceptible. Hospital length of stay served as the primary end point whereas total hospital costs represented a secondary end point. We attempted to adjust for multiple potential confounders including demographics, comorbid illnesses, infection characteristics, and severity of illness. We conducted subgroup analyses in patients who survived their hospital stay and in those requiring admission to the intensive care unit. Results: The cohort included 291 patients and 77% received initially inappropriate antibiotic therapy. Approximately one in five patients died during their hospitalization. The median length of stay among the appropriately treated population was 2 days shorter than those given initially inappropriate antibiotic therapy (7.1 vs. 9.3 days, p = .050). After adjusting for covariates in a Cox proportional hazards model, initially appropriate therapy remained associated with a reduced length of stay (hazard ratio: 0.69, 95% confidence interval: 0.51–0.92, p = .013). Median crude costs in those treated appropriately were $13,688 compared with $19,427 (p = .019). Restricting the analysis to either hospital survivors or to those needing intensive care did not alter our observations. Conclusion: Initially inappropriate antibiotic therapy for methicillin-resistant S. aureus prolongs length of stay and increases hospital costs. Efforts to lower rates of initially inappropriate antibiotic therapy for methicillin-resistant S. aureus sterile-site infections will likely improve outcomes for both patients and for healthcare institutions.Keywords
This publication has 18 references indexed in Scilit:
- Before–after study of a standardized hospital order set for the management of septic shock*Critical Care Medicine, 2006
- Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment*Critical Care Medicine, 2006
- Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumoniaCritical Care, 2006
- Changes in the Epidemiology of Methicillin-Resistant Staphylococcus aureus in Intensive Care Units in US Hospitals, 1992-2003Clinical Infectious Diseases, 2006
- MRSA—the tip of the icebergClinical Microbiology & Infection, 2006
- Appropriateness and delay to initiate therapy in ventilator-associated pneumoniaEuropean Respiratory Journal, 2006
- Methicillin-ResistantStaphylococcus aureusDisease in Three CommunitiesNew England Journal of Medicine, 2005
- Pseudomonas aeruginosaBloodstream Infection: Importance of Appropriate Initial Antimicrobial TreatmentAntimicrobial Agents and Chemotherapy, 2005
- Comparison of Mortality Associated with Methicillin‐Resistant and Methicillin‐SusceptibleStaphylococcus aureusBacteremia: A Meta‐analysisClinical Infectious Diseases, 2003
- Nosocomial Methicillin-Resistant and Methicillin-SusceptibleStaphylococcus AureusPrimary Bacteremia: At What Costs?Infection Control & Hospital Epidemiology, 1999